Restenosis after recanalization for Budd-Chiari syndrome: Management and long-term results of 60 patients

Table 2 Detailed information regarding the management and outcomes of 60 Budd-Chiari syndrome patients with restenosis

Primary recanalization	Management	Death	Remission	Non-remission
PTA alone 40	PTA alone 19 (47.5%)	HCC 2 (5%), variceal bleeding 2 (5%), liver or multiple organ failure 1 (2.5%)	14 (35%)	0
	PTA + stent 8 (20%)	HCC 1 (2.5%), liver or multiple organ failure 1 (2.5%), intracranial hemorrhage induced by hypertension 1 (2.5%), accidental death 1 (2.5%)	4 (10%)	0
	Untreated 13 (32.5%)	Liver or multiple organ failure 5 (12.5%), variceal bleeding 1 (2.5%), DIC 1 (2.5%)	2 (5%)	Abdominal distension 3 (7.5%), lower-extremity edema 1 (2.5%)
PTA + stent 20	PTA alone 10 (50%)	Liver or multiple organ failure 1 (5%)	9 (45%)	0
	PTA + stent 1 (5%)	0	1 (5%)	0
	Untreated 9 (45%)	HCC 1 (5%), variceal bleeding 2 (10%), liver or multiple organ failure 4 (20%), hepatic encephalopathy 2 (10%)	0	0

BCS: Budd-Chiari syndrome; PTA: Percutaneous transluminal angioplasty; HCC: Hepatocellular carcinoma; DIC: Disseminated intravascular coagulation.